NASDAQ:NVCR - NovoCure Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $144.75
  • Forecasted Upside: 96.70 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$73.59
▼ -3.49 (-4.53%)

This chart shows the closing price for NVCR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NovoCure Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVCR

Analyst Price Target is $144.75
▲ +96.70% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for NovoCure in the last 3 months. The average price target is $144.75, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 96.70% upside from the last price of $73.59.

This chart shows the closing price for NVCR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in NovoCure. This rating has held steady since January 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 2 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 2 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2022HC WainwrightInitiated CoverageBuy$115.00Medium
5/13/2022Piper SandlerLower Price Target$125.00 ➝ $100.00High
2/8/2022Loop CapitalInitiated CoverageBuy$200.00Medium
2/2/2022OppenheimerUpgradeMarket Perform ➝ Outperform$98.00Medium
1/20/2022Truist FinancialUpgradeHold ➝ Buy$125.00High
1/11/2022Wells Fargo & CompanyLower Price TargetEqual Weight$105.00 ➝ $70.00Low
1/6/2022Piper SandlerLower Price TargetOverweight ➝ Overweight$180.00 ➝ $130.00High
10/25/2021Piper SandlerLower Price TargetOverweight$235.00 ➝ $195.00Medium
7/30/2021Wells Fargo & CompanyLower Price TargetEqual Weight$215.00 ➝ $180.00High
7/30/2021MizuhoLower Price TargetNeutral$229.00 ➝ $200.00High
7/29/2021Piper SandlerReiterated RatingOverweight$240.00 ➝ $235.00High
7/9/2021Piper SandlerBoost Price TargetOverweight$235.00 ➝ $240.00Low
7/1/2021Northland SecuritiesInitiated CoverageBuy$250.00Low
7/1/2021MizuhoDowngradeBuy ➝ Neutral$229.00High
4/20/2021WedbushReiterated RatingNeutral ➝ Underperform$159.00 ➝ $154.00Low
4/19/2021Truist FinancialBoost Price TargetHold$132.00 ➝ $142.00Low
4/14/2021Northland SecuritiesBoost Price TargetOutperform$200.00 ➝ $250.00Medium
4/14/2021WedbushDowngradeNeutral ➝ Underperform$159.00 ➝ $154.00Medium
4/14/2021MizuhoBoost Price TargetPositive ➝ Buy$175.00 ➝ $242.00Medium
4/13/2021Wells Fargo & CompanyBoost Price TargetPositive ➝ Equal Weight$135.00 ➝ $215.00High
3/1/2021MizuhoBoost Price TargetBuy$150.00 ➝ $175.00Low
1/29/2021Truist FinancialBoost Price Target$118.00 ➝ $132.00Low
1/25/2021Piper SandlerBoost Price TargetOverweight$140.00 ➝ $225.00Low
1/12/2021WedbushBoost Price Target$110.00 ➝ $159.00Medium
10/30/2020MizuhoBoost Price TargetBuy$84.00 ➝ $150.00Low
10/29/2020Piper SandlerBoost Price TargetOverweight$125.00 ➝ $140.00Medium
9/23/2020Northland SecuritiesInitiated CoverageOutperformLow
9/18/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$116.00High
9/17/2020Piper SandlerBoost Price Target$89.00 ➝ $125.00Low
9/17/2020Truist FinancialDowngradeBuy ➝ Hold$108.00High
8/3/2020SunTrust BanksReiterated RatingBuyMedium
7/31/2020WedbushReiterated RatingNeutralLow
7/31/2020MizuhoBoost Price TargetBuy$82.00 ➝ $84.00Medium
7/30/2020OppenheimerReiterated RatingHoldMedium
7/30/2020Piper SandlerBoost Price Target$85.00 ➝ $89.00Low
7/6/2020MizuhoReiterated RatingBuy$82.00Medium
6/1/2020OppenheimerInitiated CoverageBuyLow
5/27/2020MizuhoReiterated RatingBuy$82.00High
5/1/2020SunTrust BanksLower Price TargetBuy$105.00 ➝ $90.00High
5/1/2020WedbushLower Price TargetNeutral$80.00 ➝ $78.00High
5/1/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
5/1/2020OppenheimerReiterated RatingOutperform ➝ Market Perform$102.00 ➝ $78.00High
4/19/2020Piper SandlerInitiated CoverageOverweight$85.00High
4/19/2020Evercore ISIDowngradeIn-Line ➝ UnderperformHigh
4/9/2020Evercore ISIDowngradeIn-Line ➝ Underperform$75.00 ➝ $58.00Medium
4/8/2020MizuhoLower Price TargetBuy$91.00 ➝ $82.00High
4/7/2020Piper SandlerInitiated CoverageOverweight$85.00High
4/7/2020Wells Fargo & CompanyLower Price TargetOverweight$90.00 ➝ $82.00High
3/5/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$85.00 ➝ $90.00Low
2/28/2020MizuhoReiterated RatingBuy$91.00High
1/14/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
1/7/2020MizuhoReiterated RatingBuy$91.00High
12/12/2019Wells Fargo & CompanyBoost Price Target$75.00 ➝ $85.00High
11/4/2019JPMorgan Chase & Co.Reiterated RatingHold$79.00High
9/13/2019OppenheimerBoost Price TargetBuy$85.00 ➝ $97.00Low
7/29/2019SunTrust BanksUpgradeHold ➝ BuyMedium
7/26/2019OppenheimerSet Price TargetBuy$85.00N/A
7/26/2019WedbushDowngradeOutperform ➝ Neutral$57.00 ➝ $80.00High
7/26/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$61.00 ➝ $79.00High
7/26/2019MizuhoBoost Price TargetBuy$63.00 ➝ $91.00High
7/19/2019OppenheimerSet Price TargetBuy$76.00Medium
6/28/2019OppenheimerInitiated CoverageOutperform$75.00 ➝ $75.00High
5/26/2019JPMorgan Chase & Co.Reiterated RatingBuyMedium
5/24/2019WedbushReiterated RatingOutperform$57.00High
3/19/2019SunTrust BanksInitiated CoverageHold ➝ Hold$50.00High
3/7/2019MizuhoReiterated RatingBuy$63.00Low
2/28/2019Wells Fargo & CompanyReiterated RatingHoldHigh
12/6/2018MizuhoReiterated RatingBuy$51.00Low
11/15/2018MizuhoReiterated RatingBuy$51.00Low
11/2/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformMedium
11/1/2018MizuhoReiterated RatingBuy$51.00Medium
10/30/2018Wells Fargo & CompanyReiterated RatingOutperform ➝ Market Perform$41.00 ➝ $36.00Medium
10/26/2018WedbushBoost Price TargetOutperform$55.00 ➝ $58.00Medium
10/19/2018MizuhoReiterated RatingBuy$58.00High
9/20/2018Deutsche Bank AktiengesellschaftSet Price TargetHold$44.00Low
9/19/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Positive$53.00 ➝ $58.00High
9/16/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
9/13/2018Wells Fargo & CompanyReiterated RatingBuyLow
9/7/2018WedbushReiterated RatingOutperform$50.00 ➝ $40.00High
9/6/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $48.00High
9/6/2018MizuhoReiterated RatingBuy$58.00High
7/27/2018WedbushBoost Price TargetOutperform ➝ Outperform$33.00 ➝ $40.00Low
7/27/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $44.00High
7/25/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldLow
7/16/2018Evercore ISIInitiated CoverageOutperform$46.00High
6/13/2018MizuhoReiterated RatingBuy$32.00Low
4/27/2018WedbushBoost Price TargetOutperform ➝ Outperform$29.00 ➝ $33.00Low
4/19/2018Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$23.80 ➝ $19.00Low
4/18/2018MizuhoReiterated RatingBuy ➝ Buy$28.00 ➝ $32.00High
2/23/2018Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Hold$22.00 ➝ $19.00High
2/23/2018MizuhoReiterated RatingBuy ➝ Buy$25.00 ➝ $28.00High
12/1/2017MizuhoReiterated RatingBuy$25.00High
11/20/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
10/27/2017WedbushReiterated RatingOutperform$29.00 ➝ $25.00N/A
9/6/2017MizuhoInitiated CoverageBuy$25.00Medium
7/17/2017Deutsche Bank AktiengesellschaftReiterated RatingHold$18.00 ➝ $19.00Low
(Data available from 5/25/2017 forward)

News Sentiment Rating

-0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 11 positive mentions
  • 6 negative mentions
  • 5 very negative mentions
10/27/2021
  • 3 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 4 very negative mentions
11/26/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
12/26/2021
  • 2 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
1/25/2022
  • 0 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
2/24/2022
  • 7 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
3/26/2022
  • 1 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
4/25/2022
  • 4 very positive mentions
  • 14 positive mentions
  • 5 negative mentions
  • 3 very negative mentions
5/25/2022

Current Sentiment

  • 4 very positive mentions
  • 14 positive mentions
  • 5 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

NovoCure logo
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.
Read More

Today's Range

Now: $73.59
Low: $72.49
High: $75.80

50 Day Range

MA: $78.67
Low: $57.94
High: $89.90

52 Week Range

Now: $73.59
Low: $56.51
High: $232.76

Volume

341,646 shs

Average Volume

662,644 shs

Market Capitalization

$7.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of NovoCure?

The following sell-side analysts have issued stock ratings on NovoCure in the last year: HC Wainwright, Loop Capital, Mizuho, Northland Securities, Oppenheimer Holdings Inc., Piper Sandler, StockNews.com, TheStreet, Truist Financial Co., Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for NVCR.

What is the current price target for NovoCure?

0 Wall Street analysts have set twelve-month price targets for NovoCure in the last year. Their average twelve-month price target is $144.75, suggesting a possible upside of 96.7%.
View the latest price targets for NVCR.

What is the current consensus analyst rating for NovoCure?

NovoCure currently has 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NVCR will outperform the market and that investors should add to their positions of NovoCure.
View the latest ratings for NVCR.

How do I contact NovoCure's investor relations team?

NovoCure's physical mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider's listed phone number is 441534756700 and its investor relations email address is [email protected] The official website for NovoCure is www.novocure.com. Learn More about contacing NovoCure investor relations.